Tags
Cartilage Repair
Tags
ergonomicpractices
Tags
pain management
198 results found in 111ms
Who qualifies for ChondroFiller injectionWho qualifies for ChondroFiller injection
ChondroFiller recruits the patient's own cells into a collagen scaffold placed within focal cartilage defects; candidacy requires mechanical joint stability and absence of widespread degeneration.ChondroFiller recruits the patient's own cells into a collagen scaffold placed within focal cartilage defects; candidacy requires mechanical joint stability and absence of widespread degeneration.
Allograft vs autograft for large knee cartilage defectsAllograft vs autograft for large knee cartilage defects
Autograft for knee cartilage defects larger than roughly 2–4 cm² risks replacing one area of cartilage loss with another at the harvest site. Osteochondral allografts from cadaveric donors eliminate this trade-off and achieve 5-year survival of 79–87.8%.Autograft for knee cartilage defects larger than roughly 2–4 cm² risks replacing one area of cartilage loss with another at the harvest site. Osteochondral allografts from cadaveric donors eliminate this trade-off and achieve 5-year survival of 79–87.8%.
How strong is ChondroFiller's clinical evidenceHow strong is ChondroFiller's clinical evidence
ChondroFiller produces clinically meaningful functional improvement of approximately 30 IKDC points in knee patients, sustained at three-year follow-up, but published evidence extends no further, leaving long-term durability unproven.ChondroFiller produces clinically meaningful functional improvement of approximately 30 IKDC points in knee patients, sustained at three-year follow-up, but published evidence extends no further, leaving long-term durability unproven.
How ACI and MACI differ for cartilage repairHow ACI and MACI differ for cartilage repair
MACI pre-seeds cultured chondrocytes onto a collagen membrane fixed with fibrin glue, eliminating the sutures required in earlier ACI variants. The technique enables arthroscopic implantation and supports faster recovery than open surgical approaches.MACI pre-seeds cultured chondrocytes onto a collagen membrane fixed with fibrin glue, eliminating the sutures required in earlier ACI variants. The technique enables arthroscopic implantation and supports faster recovery than open surgical approaches.
ChondroFiller injection vs knee replacementChondroFiller injection vs knee replacement
ChondroFiller is a collagen scaffold injection that recruits the patient's own repair cells to treat focal cartilage defects. Knee replacement suits end-stage, widespread wear; the choice between them depends on imaging findings, not age.ChondroFiller is a collagen scaffold injection that recruits the patient's own repair cells to treat focal cartilage defects. Knee replacement suits end-stage, widespread wear; the choice between them depends on imaging findings, not age.
ChondroFiller injection vs PRP for cartilage repairChondroFiller injection vs PRP for cartilage repair
ChondroFiller fills focal cartilage defects with a collagen scaffold; PRP modulates inflammation in diffuse wear. MRI findings, not symptoms, determine which applies.ChondroFiller fills focal cartilage defects with a collagen scaffold; PRP modulates inflammation in diffuse wear. MRI findings, not symptoms, determine which applies.
When is it too late for cartilage repair?When is it too late for cartilage repair?
Once cartilage loss becomes generalised and surfaces contact bone, no restoration procedure works; repair is viable only for focal defects.Once cartilage loss becomes generalised and surfaces contact bone, no restoration procedure works; repair is viable only for focal defects.
ChondroFiller availability across EuropeChondroFiller availability across Europe
ChondroFiller is an injectable collagen scaffold that gels in place and recruits the patient's own cells to repair cartilage defects. CE-marked Class III in Europe, it is available in UK private clinics under the brand Liquid Cartilage™, from £3,000 per injection.ChondroFiller is an injectable collagen scaffold that gels in place and recruits the patient's own cells to repair cartilage defects. CE-marked Class III in Europe, it is available in UK private clinics under the brand Liquid Cartilage™, from £3,000 per injection.
AMIC versus MACI for focal cartilage repairAMIC versus MACI for focal cartilage repair
AMIC repairs focal cartilage defects in one operation: drilling channels into damaged cartilage releases a blood clot rich in stem cells, which a collagen membrane then stabilises and concentrates to guide tissue repair. A 2025 trial found it equivalent to MACI at two years.AMIC repairs focal cartilage defects in one operation: drilling channels into damaged cartilage releases a blood clot rich in stem cells, which a collagen membrane then stabilises and concentrates to guide tissue repair. A 2025 trial found it equivalent to MACI at two years.
ChondroFiller durability vs Arthrosamid and hyaluronic acidChondroFiller durability vs Arthrosamid and hyaluronic acid
ChondroFiller's collagen scaffold breaks down in six to twenty-four months, but the clinical benefit lasts one to five years or longer because the material recruits the patient's own progenitor cells to support cartilage repair, not to act as permanent filling.ChondroFiller's collagen scaffold breaks down in six to twenty-four months, but the clinical benefit lasts one to five years or longer because the material recruits the patient's own progenitor cells to support cartilage repair, not to act as permanent filling.
Chondroplasty for knee cartilage damageChondroplasty for knee cartilage damage
Chondroplasty removes loose cartilage fragments that cause catching and grinding, relieving mechanical symptoms, but does not rebuild the cartilage itself; it is palliative, not restorative.Chondroplasty removes loose cartilage fragments that cause catching and grinding, relieving mechanical symptoms, but does not rebuild the cartilage itself; it is palliative, not restorative.
ChondroFiller success rates in practiceChondroFiller success rates in practice
ChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.ChondroFiller, which recruits a patient's own cells to fill cartilage defects, produces meaningful pain reduction and improved joint function in 70–85% of patients within one to five years; but success depends on selecting younger patients with focal defects in otherwise healthy joints.
198 results found in 111ms